March 15, 2017
(CNBC) – The recently discovered, hotly contested gene-editing enzyme CRISPR is poised to change the way we treat, even cure, many diseases. But treatment will come years before talk of any “cure” is reasonable, and researchers know where they’d put their money if they had to bet on which kind of disease will be the first to the clinic. Bet on CRISPR succeeding first against a rare, single mutation.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.